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Introduction: Cisplatin in combination with vinorelbine has re-
ported an optimal activity/tolerance ratio when used in combination
with radiotherapy in locally advanced unresectable non-small cell
lung cancer. The currently available oral formulation of vinorelbine
should be easier to use assuming a similar activity profile. An
international phase II trial with vinorelbine oral and cisplatin as
induction followed by oral vinorelbine and cisplatin with concom-
itant radiotherapy was implemented to evaluate the efficacy in terms
of objective response (OR) following this combination as primary
end point and duration or response, progression-free survival, over-
all survival, and safety as secondary endpoints.
Material and Methods: The study included patients between 18
and 75 years, with histologically proven untreated locally advanced
inoperable stage IIIA/IIIB (supraclavicular lymph nodes and pleural
effusion excluded) non-small cell lung cancer, adequate bone mar-
row, hepatic and renal function, Karnofsky performance status
80%. Patients were treated with oral vinorelbine 60 mg/m2 day 1,8
cycle 1 and 80 mg/m2 day 1,8 cycle 2 (if no grade 3–4 toxicity) and
cisplatin 80 mg/m2 day 1 every 3 weeks for 2 cycles as induction.
Patients without progression received oral vinorelbine 40 mg/m2 day
1, 8 and cisplatin 80 mg/m2 day 1 every 3 weeks for 2 more cycles
with radiotherapy 66 Gy in 6.5 weeks.
Results: Patient and disease characteristics (n  54) included:
median age 57 years; female sex 24%; stage IIIA 48% and IIIB
52%; Squamous carcinoma 59%, Karnofsky performance status
100% (range, 80–100%) 50%, patients 5% weight loss at baseline
7%. Relative dose intensities of oral vinorelbine/cisplatin were
86%/93% and 97%/98% at induction and in combination with
radiotherapy, respectively. Forty-one patients (76%) increased oral
vinorelbine from 60 to 80 mg/m2 day during induction (reasons for
nonescalation: hematological 7 patients, nonhematological 2 pa-
tients, error 4 patients). After two cycles of chemotherapy induction,
the OR intent-to-treat in the 54 patients was 37%. Toxicities during
induction were as follows: Neutropenia G3–4 (28%), Febrile Neu-
tropenia (7%), nausea G3 (11%), vomiting G3–4 (9%), anorexia G3
(4%), diarrhea G4 (2%), constipation G3 (2%). Forty-seven out of
54 (87%) patients received concomitant chemo-radiotherapy.
Median radiotherapy delivered dose was 66 Gy. Tolerance: 9%
G3 Neutropenia; 4% G3 dysphagia/radiation; 2% G3 radiation derma-
titis. Late pulmonary fibrosis was reported in one patient (1.8%). One
month after completion of chemo-radiotherapy, the overall OR
intent-to-treat in the 54 patients was 54% (95% CI: 40–67%). With
a median follow-up of 37 months (95% CI: 34–41) the median
progression-free survival and overall survival were: 12.5 (95% CI:
9.6–16.4) and 23.4 (95% CI: 17.6–29.8) months, respectively.
Conclusion: Oral vinorelbine in combination with cisplatin is an
effective combination in stage IIIA/IIIB patients. The excellent
tolerance profile allowed to complete concomitant chemo-radiother-
apy in 87% of patients. Oral vinorelbine in combination with
cisplatin is a new and promising option that facilitates the adminis-
tration of concomitant chemo-radiotherapy with high rates of treat-
ment completion.
Key Words: Lung cancer, Local advanced, Concomitant radio-
therapy, Oral vinorelbine.
(J Thorac Oncol. 2008;3: 994–1002)
Non small cell lung cancer (NSCLC) is the most frequenttype of lung cancer, accounting as the main cause of
cancer death in the world, with at least one third of patients
presenting locally advanced (stage III) disease at diagnosis.1
Stage III patients are not an uniform group with heteroge-
neous patterns of disease extension, different prognosis, and
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distinct treatment approaches, ranging from surgery, radio-
therapy (RT) or chemotherapy (CT) alone, to the combination
of all of them. In patients with unresectable stage IIIA/B
NSCLC the treatment address bulky pulmonary and/or me-
diastinal disease and systemic micro metastases. The high
rates of loco regional failure and the tendency to develop
systemic disease due to micrometastatic spread present at the
time of initial diagnosis are limiting factors of successful
outcome.
In the treatment of locally advanced NSCLC, combined
RT and cisplatin (CDDP)-based CT is superior to RT alone,
and reduces the relative risk of death by about 13%.2 So far,
third-generation platinum-based CT regimens allow for an
optimal disease control when used in combination with RT.
Combining the two modalities simultaneously in lo-
cally advanced disease has a theoretical advantage based on
several possible mechanisms of interaction3–5 between CT
and RT: (a) activity on different cell subpopulations; (b)
CT-induced cell cycle synchronization into the more radio-
sensitive G2/M phase; (c) enhancement of radiation-induced
cytotoxicity by inhibiting tumor-cell repopulation.
The relative merits of a concurrent schedule combining
CT and RT versus their sequential administration have been
confirmed by several trials.6,7 Furthermore, a recent meta-anal-
ysis on individual patient data from 1205 patients enrolled in 6
randomized studies with either concomitant or sequential
chemo-radiotherapy reported that the concurrent approach was
superior with a significant reduction in the incidence of local
relapse (HR  0.77 [CI 95%: 0.62–0.95]; P  0.01) and an
overall benefit of 4.5% improvement in overall survival (HR 
0.84 [CI 95%: 0.74–0.95]; P  0.004).8
CDDP-based combinations with GEM, paclitaxel
(PCT) or NVB have been tested in a randomized CALGB
phase II trial.9 Patients with unresectable stage III NSCLC
received induction CT (CDDP and NVB, or PCT, or GEM)
after concomitant chemo-radiotherapy with the same agents.
The three schedules had similar efficacy, with response rates,
ranging from 67 to 74%, and 1-year survival rates from 62 to
68%. However, these schedules reported different safety
profiles, with CDDP-NVB inducing less toxicity than the
other 2 combinations, especially in terms of grade 3–4
oesophagitis (NVB 25%; PCT 39%; GEM 52%).
Oral vinorelbine (NVBo) is a new formulation with
evidence of single agent activity in first line CT of advanced
NSCLC, reported in a randomized phase II study versus
intravenous (iv) vinorelbine. In patients given oral vinorel-
bine, the overall response was observed in 14% of evaluable
patients, with a median progression-free survival and a me-
dian survival of 3.2 and 9.3 months, respectively.10 These
results suggest that oral vinorelbine delivered at equivalent
doses is at least as effective as i.v. vinorelbine, with both
response rate and survival falling within the range of what has
commonly been reported with single agent i.v. vinorelbine in
randomized trials.11,12 Based on the known efficacy of iv
NVB and CDDP in advanced NSCLC, the demonstrated
superiority of CT over RT alone in locally advanced disease,
and the evidence that both CDDP and NVB act as radiation
enhancers,13–15 we decided to initiate a phase II trial with
NVBo and CDDP in locally advanced NSCLC. During the
induction phase, the NVBo dosing in this trial was aimed to
achieve equivalent blood exposure as NVBi.v. Bioequiva-
lence trials have reported an absolute bioavailability of NVBo
of 37.8  16%16 with a reliable NVB correspondence be-
tween 80 mg/m2 oral and 30 mg/m2 iv.17 During concomitant
CT-RT, NVBo dosing was calculated on both the NVBo abso-
lute bioavailability and previous experience with NVB iv, where
doses between 15 mg/m218 and 20 mg/m215 were used in
combination with CDDP and concomitant RT at 60 Gy.
The primary objective of the study was to evaluate the
objective response based on the SWOG modified criteria.19
Secondary efficacy objectives included duration of response,
progression-free survival, and overall survival.
PATIENTS AND METHODS
This was a multicenter, open-label, nonrandomized,
phase II study of NVBo in combination with CDDP as
induction treatment, followed by the same CT given concom-
itantly with RT in patients with unresectable, locally ad-
vanced NSCLC. Eligibility criteria included: (i) age between
18 and 75 years, with score 18/20 at functional evaluation
scales ADL and IADL for patients between 70 and 75 years;
(ii) histologically proven NSCLC; (ii) previously untreated
locally advanced inoperable stage IIIA (only N2) and stage
IIIB disease (N3 patients and/or supraclavicular lymph node
involvement and/or malignant pleural effusion excluded, with
exception of N3 involvement limited to contralateral medi-
astinal lymph-nodes and with no more than 30% of both
lungs volume to be receiving dose of 20 Grays or more); (iv)
Karnofsky Performance Status 80%; (v) weight loss 10%
within the previous 3 months; (vi) life expectancy 12
weeks; (vii) adequate bone marrow, hepatic and renal func-
tion; (viii) presence of at least one bidimensionally measur-
able lesion; (ix) absence of any psychologic, familial, socio-
logical or geographical conditions potentially hampering
compliance with the study protocol and follow-up schedule;
(x) signed informed consent prior to any protocol-specific
procedure. The study was conducted in accordance with the
ethical principles stated in the Declaration of Helsinki and
subsequent amendments, and in compliance with Good Clin-
ical Practice Guidelines.20
Radiologic examination included chest radiograph,
computed tomography scanning or magnetic resonance im-
aging of the chest with inclusion of upper abdomen including
adrenal glands and liver, brain (if neurologic symptoms), and
bone scan performed within 4 weeks from registration.
Study Assessments
Tumor assessment was performed every two cycles.
The primary efficacy parameter was defined as the best
confirmed response recorded from the start of treatment until
disease recurrence or progression, expressed as the percent-
age of complete (CR) and partial responses (PR) excluding
unconfirmed responses. CR required disappearance of all
target lesions, and PR required a 30% or more decrease in the
sum of longest diameters of target lesions taking as reference
the baseline values. Progressive disease (PD) was defined as
a 20% or more increase in the sum of longest diameters of
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target lesions taking as reference the smallest sum recorded
since the treatment started, or the appearance of one or more
new lesions. Stable disease was defined as either insufficient
shrinkage to qualify for PR or insufficient increase to qualify
for PD.
Safety evaluations included physical examination and
vital signs, Karnofsky Performance Status, complete blood
counts, serum biochemistry, clinical safety, and adverse
events graded according to National Cancer Institute Com-
mon Toxicity Criteria version 2.021 except for febrile Neu-
tropenia (Pizzo’s definition).22 Hematological parameters
were controlled on day one and eight of every cycle.
The duration of follow-up period was calculated from
the end of the study evaluation until death. Survival informa-
tion was collected approximately every 3 months until death.
Statistical Analysis
The one-sample multiple-testing procedure for phase II
clinical trials as described by Fleming was used.23 With 45
evaluable patients, a null hypothesis for the true response rate
of 20% and an alternative hypothesis of 40%, the type I error
 was less than 5% and the type II error  was less than 10%.
Assuming a 10%-rate of nonevaluable patients, a total of 50
patients were to be enrolled to obtain a sample size of 45
evaluable patients. The analysis was performed on an intent-
to-treat basis on registered and treated patients and in the
evaluable population. The primary efficacy analysis was the
objective response rate on the intent-to-treat population after
completion of concomitant chemo-radiotherapy or during/
after induction CT for patients withdrawn before concomitant
chemo-radiotherapy. Secondary analyses included duration
of response, progression-free survival and overall survival.
To describe time dependent parameters, Kaplan Meier curves
and life tables were provided. Considering safety analysis,
worst NCI-CTC version 2.0 grade was reported by patient
and by cycle on all treated patients. The first patient was
included on June 19th 2002, the last one on December 17th
2003 and the cut-off date for the final analysis was on July
31st 2006. The median follow-up was 37 months (CI 95%:
34–41).
Treatment Plan
After registration, patients received two cycles of in-
duction CT, based on NVBo administered once a day at the
dose of 60 mg/m2 on days 1 and 8 in the first cycle and at the
dose of 80 mg/m2 in the second cycle (cycles repeated every
21 days) (Figure 1). CDDP was administered after NVBo and
after saline hydration at the dose of 80 mg/m2 on day 1, every
3 weeks. During the concomitant phase, patients received
NVBo once a day at the dose of 40 mg/m2 on days 1 and 8,
every 3 weeks, for 2 cycles. CDDP was delivered at the same
dose as during induction, with hydration given according to
the institution’s routine. It was recommended to take NVBo
on day 1 with some food and systematic prophylactic anti-
emetic treatment 30 to 60 minutes before starting cisplatin
infusion. Antiemetics and corticoids were administered ac-
cording to institution protocol. On day 8, systematic anti-
emetic treatment with 5-HT3 antagonist (e.g., granisetron 2
mg or ondansetron 8 mg orally) had to be administered 30
minutes before NVBo intake, followed by metoclopramide
10 mg twice a day orally. Metoclopramide three times a day
could be administered if necessary. Steroids, given as pre-
ventive antivomiting treatment, were allowed.
Induction treatment was administered for at least two
cycles. At the end of the second cycle the tumor response was
assessed. Patients with PD were removed from the study. Pa-
tients showing an objective response (CR or PR) or no change
(NC) of the disease received two additional cycles of CDDP/
NVBo concurrently with chest irradiation. In case of docu-
mented progression occurring before the first disease evaluation
(6 weeks after treatment start), the treatment was discontinued
and the response to treatment was assessed as early progression;
and the patient was removed from the study.
Chest irradiation started concurrently with the CT,
starting on day 1 of the third cycle. Radiation therapy was
given using photon beams (energy higher than 6MV). Pro-
phylactic irradiation of the ipsilateral hilum and mediastinum
was recommended. A total dose of 66 Gy (at the ICRU point)
was delivered to the Planning Target Volume for the tumor
(PTVt) in daily fractions of 2 Gy for 6.5 consecutive weeks (5
fractions/wk), starting on day 28 of the second cycle of
FIGURE 1. Treatment design.
Krzakowski et al. Journal of Thoracic Oncology • Volume 3, Number 9, September 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer996
induction CT, with a maximum of 1-week delay. The total
dose to the Planning Target Volume for the nodes (PTVn)
was 46 Gy using the same fractionation schedule.
Chemotherapy Dose Modification
Treatment was modified in case of hematological
and/or nonhematological toxicities. All dose adjustments
were made according to the system showing the greatest
degree of toxicities. If the study treatment could not be
administered within 2 weeks due to any toxicity, it was
definitively discontinued. Dose cancellation and/or modifica-
tion were based on blood count results obtained within 24
hours before dosing. During induction phase, the NVBo
intake of day 1 had not to be dissociated from the CDDP
injection; if the latter was delayed for any toxic reason, the
same applied for the NVBo intake of day 1. NVBo dose
adaptation during induction CT and concomitant chemo-
radiotherapy is reported in Table 1.
Treatment with growth factors was given to patients
who experienced febrile Neutropenia or neutropenic infection
according to the institution’s routine. In case of neurologic
grade 0–1 toxicity, no dose modification was applied. In case
of grade 2 neurotoxicity, only cisplatin dosing was reduced
by 50% for the further administrations. CDDP administration
was based on creatinine clearance. For other grade 3 tox-
icities, including also mucositis, oesophagitis, stomatitis, and
dermatitis, CT had to be withheld for a maximum of 15 days
from the planned date of administration.
Radiotherapy was discontinued in case of patients’
refusal, metastatic spread, worsening of PS, side effects or
intercurrent illness incompatible with the treatment. Namely,
irradiation should be stopped in case of oesophagitis requir-
ing parenteral nutrition, poly morpho nuclears 500/mm3
and/or febrile Neutropenia and/or platelets 50,000/mm3. Ra-
diotherapy was discontinued until platelets 50,000/mm3, poly
morpho nuclears 500/mm3 and patient apyrexia.
Treatment with other antineoplastic agents was not
allowed, resulting in patient’s withdrawal.
RESULTS
From June 2002 to December 2003, 54 patients were
registered and treated. Patients’ characteristics are detailed in
Table 2. Overall, 76% were males. The median age was 57.5
years, with 17 patients aged 65 years. Performance Status
90 to 100% was reported in 83% of patients.
All 54 patients were evaluable for safety and 52 pa-
tients for tumor response (Figure 2). The two not evaluable
patients died after two cycles before response evaluation for
massive hemoptysis and cardiac failure, respectively; the first
event was considered as unrelated to study drug, the second
as dubious. Forty one patients (76%) received the maximum
TABLE 1. Dose Modification for Haematological Toxicity
NCI-CTC Grading Neutrophils (109/liter) Platelets (109/liter) Oral Vinorelbine Cisplatin
Induction therapy–d 1 (cycle 2)
0–1 1.5 and 75 No dose modification
2 1  PMN  1.5 and/or 50  PLT  75 Administration delayed.
Restart at 80 mg/m2
3–4a 1 and/or 50 Administration delayed.
Restart at 60 mg/m2
Concomitant chemoradiotherapy–d 1 (cycle 1–2)
0–1–2 1.0 and 50 No dose modification
3–4a 1.0 and/or 50 Administration delayed.
Restart at the same dose
Induction and concomitant chemo-radiotherapy–d 8 (all cycles)
0–1–2 1.0 and 50 No dose modification
3–4a 1.0 and/or 50 Administration cancelled
a In case of grade 4 neutropenia, blood count should be performed every 2 days until recovery of PMN 0.5
NCI-CTC, National Cancer Institute Common Toxicity Criteria
TABLE 2. Patients’ Characteristics
Characteristic No. (%)
Included 54
Sex
Male 41 76
Female 13 24
Age, yr (range) 57.5 (41.5–71.4)
KPS
80 9 17
90 18 33
100 27 50
Histology
Squamous/epidermoid 32 59
Adenocarcinoma 15 28
Large cell 1 2
Other NSCLC 6 11
Stage at diagnosis
IIIA 26 48
IIIB 28 52
Prior surgery 1 1.9
Median time from diagnosis to
study entry, (range)
0.1 (0–1.8)
KPS, Karnofsky performance status; NSCLC, non-small cell lung cancer; yr, year.
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number of cycles according to the protocol. Thirteen patients
had treatment discontinuation for progression (5 patients),
adverse event (5 patients), worsening of general status (1
patient), and death related neither to adverse events nor to
progression (2 patients).
Overall, 199 cycles of CT were delivered, 108 cycles
during induction and 91 during concomitant chemo-radio-
therapy. On day one, 35 cycles were delayed of 4 days or
more, with 8 and 27 cycles delayed during induction and
concomitant phase, respectively. Hematological toxicity was
the main reason (14 cycles, 40%), followed by administrative
reasons (9 cycles, 26%), patients decision (4 cycles, 11%),
nonhematological toxicity (2 cycles, 6%), non study drug
related adverse event (2 cycles, 6%), investigator mistake (1
cycle, 3%) and other unspecified reason (3 cycles, 9%). Of
note, according to the protocol, the day 1 of the cycle 3 was
to be administered concomitantly with RT and delays were
due to radiation planning in 3 patients.
On day eight, only 11 cycles of NVBo administration
were delayed for 3 days or more or cancelled: ten cycles and
one cycle cancelled during induction and concomitant phase,
respectively. Nonstudy drug adverse event was the main
reason (4 cycles, 37%) followed by hematological (3 cycles,
27%), nonhematological toxicity (3 cycles, 27%), and Christ-
mas celebration (1 cycle, 9%).
The median dose intensity of NVBo was 40.2 mg/
m2/wk and 25.8 mg/m2/wk during induction and concomitant
phase, respectively, whereas its median relative dose intensity
was 86.1% and 96.8%, respectively. The median dose inten-
sity and relative dose intensity of cisplatin during the respec-
tive phases of treatment were as follows: 24.8 versus 26.2
mg/m2/wk and 93.1% versus 98.2%. NVBo was escalated on
the second cycle of induction CT to 80 mg/m2 in 41 patients
(76%). Dose increase was not possible in 13 patients (24%)
due to drug-related hematological (7 patients) or nonhema-
tological toxicity (2 patients), protocol violation (4 patients).
Radiotherapy Delivery
Median radiation dose delivered in 47 patients during
concomitant treatment was 66 Grays (SD  4.1) and 44
Grays (SD 7.6) for PTVt (planned treatment volume –
tumor) and PTVtn (planned treatment volume – tumor 
nodes), respectively. Median number of RT weeks was 6.6
(SD 1.7) and 4.1 (SD 1.5) for PTVt and PTVtn, respectively.
Response
The response evaluation has been performed on the
Intention To Treat population (54 patients). Twenty patients
(37%) achieved PR after the first 2 cycles of induction CT,
NC was found in 27 (50%) and PD in 3 (6%) patients, with
4 (7%) nonevaluable (Table 3). After concomitant chemo-
radiotherapy, 1 CR and 28 PR were reported (an overall
response rate of 53.7% 95% CI [39.6–67.4]). On the Inten-
tion To Treat population of 54 patients, with a median
follow-up of 36.9 months (95% CI: 33.6–41.3), the median
duration of response was 17.2 months (95% CI [12.6–30.2]),
with a PFS of 12.5 months (95% CI [9.6–16.4]) and an OS of
23.4 months(95% CI [17.6–29.8]) (Figure 3) with 1-year and
2-year survival rates of 74.1% and 48.1%, respectively.
At the study cut off of July the 31st 2006, 40 patients
out of 54 had documented relapse. Local and distant relapses
FIGURE 3. Response Duration.
TABLE 3. Objective Response After Induction and
Concomitant Therapy (Intention To Treat Population)
Overall Response
After
Induction
Therapy
After
Concomitant
Therapy
No. patients 54 (100%) 54 (100%)
Complete response (CR) — 1 (1.9%)
Partial response (PR) 20 (37.0%) 28 (51.9%)
Overall response 20 (37.0%) 29 (53. 7%)
No change (NC) 27 (50.0%) 20 (37.0%)
Progressive disease (PD) 3 (5.6%) 3 (5.6%)
Non evaluable (NE) 4 (7.4%) 2 (3.7%)
Median duration of response (mo) 17.2 (95% CI 12.6–30.2)
Progression-free survival (mo) 12.5 (95% CI 9.6–16.4)
Median survival (mo) 23.4 (95% CI 17.6–29.8)
FIGURE 2. Patient disposal.
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were documented in 22 (55%) and 18 (45%) patients, respec-
tively, with 39% of distant relapses (7 patients) in Central
Nervous System.
Safety
During induction CT, hematological toxicity was the
main side effect, with 9 patients (17%) and 6 patients (11.1%)
presenting grade 3 and 4 neutropenia, respectively, meaning
8.3% and 6.5% of grade 3 and 4 toxicity out of 108 cycles
(Table 4). Other grade 3–4 toxicity reported during induction
CT was: grade 3 anemia (1.9% of patients, 0.9% of cycles),
grade 3 leucopenia (3.7% of patients, 2.8% of cycles). Febrile
Neutropenia was reported in 4 patients (7.4% of patients and
3.7% of cycles). No grade 3–4 thrombocytopenia was re-
corded. Main nonhematological toxicities were: grade 3 nau-
sea in 6 patients (11.1%) and grade 3–4 vomiting in 3 (5.6%)
and 2 (3.7%) patients, respectively. During concomitant
chemo-radiotherapy as hematological toxicity only grade 3
neutropenia was recorded in 4 patients (8.5%), associated in
one patient (2.1%) with infection. As nonhematological tox-
icity, grade 3 dysphagia/radiation was the main side effect,
reported in 2 patients (4.3%). Late pulmonary fibrosis was
reported in one patient (1.8%).
DISCUSSION
The management of patients with stage III NSCLC
becomes increasingly complex, with a multidisciplinary ap-
proach for staging and management.24 Treatment strategies
for stage III have evolved substantially during the last decade
and are focused on eradicating cancer from the loco-regional
and distant compartments. The simultaneous treatment of
both local and distant sites of disease and the opportunity for
synergy between chemo- and RT enhances the disease control
and may ultimately prolong survival.25 The concomitant use
of NVB-CDDP and RT has been reported more effective than
sequential NVB-CDDP and RT in stage IIIB or inoperable
IIIA, and coupled with an acceptable safety profile.26 Zat-
loukal27 compared the safety and efficacy of concurrent
CT-RT and sequential CT followed by RT, with CT consist-
ing of CDDP and NVB, in patients with locally advanced
NSCLC. In this study population, concurrent CT-RT demon-
strated significant benefit in terms of response rate, overall
survival, and time to progression over sequential CT followed
by RT. CDDP in combination with NVB is commonly used
in Europe, whereas in North America carboplatin (CBDCA)
in combination with PCT is the most frequently employed
combination. Nevertheless, significant differences in efficacy
have been reported between CDDP and CBDCA in stage
IIIB/IV NSCLC, with CBDCA-based CT associated with a
significantly higher risk of death.28 A regimen of confirmed
activity in early stages of NSCLC would be the logical option
for treatment of locally advanced disease. CBDCA in com-
bination with PCT failed to produce significant survival
FIGURE 4. Progression-Free Survival and Overall Survival
(ITT Population, N  54 Patients). ITT, intention to treat.
TABLE 4. Haematological/Nonhaematological Safety (Per Patient)
Induction Chemotherapy
No. Patients  54
Concomitant
Chemo-Radiotherapy
No. Patients  47
Grade 3 Grade 4 Grade 3 Grade 4
n % n % n % n %
Anemia 1 1.9 — — — — — —
Leukopenia 2 3.7 — — 2 4.3 — —
Neutropenia 9 16.7 6 11.1 4 8.5 — —
Thrombocytopenia — — — — — — — —
Febrile neutropenia (Pizzo) 4 (7.4%)
Nausea 6 11.1 — — 2 4.3 — —
Vomiting 3 5.6 2 3.7 1 2.1 1 2.1
Fatigue — — — — 1 2.1 — —
Constipation 1 1.9 — — — — — —
Diarrhoea — — 1 1.9 — — — —
Anorexia 2 3.7 — — 1 2.1 — —
Dysphagia/radiation — — — — 2 4.3 — —
Infection  Gr 3–4 ANC — — — — 1 2.1 — —
Radiation dermatitis — — — — 1 2.1 — —
ANC, absolute neutrophils count.
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improvement compared with control in stage IB completely
resected NSCLC patients.29 A large meta-analysis on CDDP
and NVB in adjuvant setting confirmed that this combination
significantly improved survival over control in stage II and
stage III patients.30 GEM, taxanes, and NVB are the third
generation compounds which have shown similar efficacy in
numerous randomized trials summarized in a most recent
meta-analysis.31 The different toxicity profile of these agents
imposes a risk-benefit analysis when facing the daily practice.
The CDDP-based combination with NVB seems to offer the
better safety profile coupled with, at least, similar benefits in
terms of efficacy when used concomitantly with RT. In the
nineties, several oral anticancer agents have been developed
in NSCLC because oral CT may simplify treatment for
patients and change their perception of treatment. Critical
factors for the choice of an oral agent are the efficacy
comparable with iv CT, at least similar toxicity profile, and
reliable bioavailability. Oral NVB has produced similar re-
sults in advanced NSCLC compared with its iv formulation.
A recent large phase III trial showed comparable efficacy of
NVBo in comparison with docetaxel when both agents were
combined with CDDP.32,33 The oral formulation has been
tested in a patient preference trial in advanced NSCLC. Oral
NVB plus platinum salt was preferred by 3 out of 4 patients,
because their everyday life was less affected due to the
shorter time spent in clinic and the possibility of taking day
8 dose at home.34 This advantage is likely to be more evident
in the concomitant chemo-radiotherapy setting. Moreover,
during chemo-radiotherapy there is a need in optimizing the
delivery of effective doses of CT while maintaining an
optimal dose intensity. In the current trial, the mean dose
intensity of NVB in combination with RT was 96.8%, almost
identical as that planned, confirming that the use of an oral
CT was minimally impaired by oesophagitis. The optimal
dose intensity of NVBo and CDDP was coupled with low
rates of grade 3 oesophagitis (4.3% of patients). As a result,
all responding and NC patients completed the planned treat-
ment. The optimal dose intensity was achieved without in-
creased radiation pneumonitis, delayed pulmonary fibrosis or
organ related toxicities frequently reported in other chemo-
radiotherapy trials.35,36 The convenience of an oral formula-
tion permitted to optimize the RT delivery, with more flexi-
bility for daily appointments and preservation of venous
access for further treatments.
Control of thoracic disease is not adequate in approxi-
mately 80% of patients treated with conventional RT.37
The dose of 60 Gy was established more than 30 years
ago38 and there is a continuing search in optimizing the
delivery of RT through a better definition of tumor volumes,
doses, and intensity of delivery. In the current international
phase II trial, three-dimensional (3D) conformal technique
was mandatory in all institutions. This approach in a selected
patient population, well balanced between stage IIIA and
IIIB, allowed an optimal local control, with minimal side
effects and a median duration of response and overall survival
of 17.2 and 23.4 months, respectively. Interestingly, the long
disease control was counterbalanced by an intriguing inci-
dence of CNS relapse as first site in 7 out of 18 patients
(39%). The increased incidence of CNS metastases associ-
ated with a longer survival has been reported in patients with
locally advanced NSCLC treated by radiation and CT39 The
use of induction CT followed by concomitant CT-RT was
feasible and accepted by all participating centers, since it
allowed sufficient time for RT planning without delaying the
start of the treatment. Another interesting approach may be
the use of concurrent chemo-radiotherapy followed by addi-
tional CT as consolidation or maintenance treatment. The
Southwest Oncology Group pilot trial tested this approach
with an encouraging median survival time in excess of 2
years.40 Nevertheless, the choice of agents should be careful
evaluated, considering the risk of late pulmonary effects.
Sekine36 reported the results of a trial on consolidation
therapy with docetaxel after concomitant chemo-radiotherapy
with CDDP and NVB. This type of regimen produced a
promising overall survival of 30.4 months, with a 1-2-3 year
survival rates of 80.7%, 60.2%, and 42.6%; respectively.
Anyway, the author reported that the majority of patients
discontinued consolidation because of the high incidence of
pneumonitis, with two treatment-related deaths.
CONCLUSIONS
Concomitant chemo-radiotherapy for locally advanced
NSCLC has become a standard of care. Several third-gener-
ation drugs are available for concomitant treatment and the
choice should follow evidence-based medicine with a careful
evaluation of both the results produced by each agent in terms
of risk/benefit and its advantages for patients. Vinorelbine iv
is the third-generation drug with an efficacy confirmed in
randomized trials coupled with an optimal tolerance profile
when delivered in combination with optimal RT doses. A
combination of NVB and CDDP may be used safely with
high rates of treatment completion. The new oral formulation
of vinorelbine has reported comparable efficacy in advanced
NSCLC than the intravenous formulation. The current trial is
the first international experience where the combination of
CDDP with oral vinorelbine reported an optimal efficacy
coupled with a most favorable safety profile. The oral for-
mulation of vinorelbine simplifies the administration of con-
comitant RT and its combination with cisplatin, with high
rates of treatment completion, keeps this combination as a
suitable CT concomitantly with RT. The favorable results
reported in the current trial in terms of overall survival
supported by positive data in adjuvant therapy with NVB/
CDDP suggest that further CT with NVBo-CDDP may have
a role in the postchemo-radiotherapy consolidation/mainte-
nance treatment setting of loco-regionally advanced NSCLC.
This is the basis of an ongoing phase III trial with CDDP and
NVBo given concomitantly with irradiation to all patients
with stage III NSCLC in patients without tumor progression
randomized to receive either 2 more cycles of CDDP and
NVBo or control.41
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